title: Isotretinoin in treatment of acne: its efficacy, side effects, and recurrence rate of disease.
abstract: BACKGROUND
  Acne is a chronic inflammatory disease of pilosebaceous units. In addition to an unpleasant appearance, it may result in scarring in some cases. Despite the introduction of different treatments, oral isotretinoin is the most effective treatment and affects all the factors involved in the pathogenesis of this disease. This study was performed on patients with acne to examine the therapeutic effects, recurrence rate, and adverse effects of this drug.
  
  
  METHODS
  One hundred patients with acne, who were visited at the Bou-Ali Hospital during 2000 - 2001, and found eligible to take part in this study were selected. The severity of acne was graded at the beginning, during, and after a 6-month treatment course with oral isotretinoin. Necessary laboratory tests were done.
  
  
  RESULTS
  The data of 83 of 100 patients who continued the treatment for 6 months were analyzed. The mean +/- SEM severity score of acne improved from 3.15 +/- 0.10 to 0.58 +/- 0.09 (P < 0.0001). Complete cure was achieved in 65% of patients. The mean +/- SEM follow-up was 8.7 +/- 2.3 months and the acne severity score was 1.04 +/- 0.13 during the follow-up period. Overall, the recurrence rate was 19%; 4% of patients had to undergo retreatment. A rise in triglyceride level was the only significant laboratory alteration observed.
  
  
  CONCLUSIONS
  Oral isotretinoin appears to have favorable results and the least adverse effects in treatment of carefully-selected patients with acne.
authors.affiliation: Department of Dermatology, Skin Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, Iran. fghalamkarpour@yahoo.com
authors.forename: Fariba
authors.initials: F
authors.lastname: Ghalamkarpour
authors.forename: Soheila
authors.initials: S
authors.lastname: Nasiri
mesh_terms: D000152:Acne Vulgaris / Q000175:diagnosis / Q000188:drug therapy*; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015474:Isotretinoin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D012008:Recurrence; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D015474:Isotretinoin